Clinical Trial Detail

NCT ID NCT03106415
Title Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Mayo Clinic
Indications

triple-receptor negative breast cancer

Therapies

Binimetinib + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.